Date post: | 15-Apr-2017 |
Category: |
Education |
Upload: | satish-khadia |
View: | 1,574 times |
Download: | 3 times |
Plant molecular farming for recombinant therapeutic
proteins
Ph.D. (Genetics & Plant Breeding)
K. Satish
2
Outlines
Introduction
General strategy in Molecular farming
Different production systems
Applications
Case studies
Biosafety issues
Conclusions
Future thrust
3
Introduction
Plant molecular farming is the production of pharmaceutically important and commercially valuable diagnostic proteins and/or industrial enzymes in plants.
Combination of biotechnology and agriculture to produce new biomolecules for the benefits of human being
It is also known as biopharming or gene pharming.Molecular farming started about 20 years ago with the promise to
produce therapeutic molecules. Some therapeutic molecules are very expensive to produce. Falls under the category of green biotechnology.
Sahu et al., 2014
4
Molecular Farming Milestones
1989- First plant made
antibody IgG1 in tobacco
1986- First plant derived
protein rhGH in tobacco
1992- HBsAg in tobacco
1995- Oral vaccinepotato
1998- First clinical trail of plant derived
pharmaceutical protein
2003- Commercialization
Trypsin- Maize
1997- Commercialization
Avidin - Maize
2000- HGH produced in tobacco
chloroplasts
2006- Plant – made vaccine approved by
USDA
2006- First Commercialized
plant-made Antibody
2012- Plant – made vaccine approved for
human use
Brief history of molecular farming
Fischer et al. 2013
5
General strategy in molecular farming
Sahu et al., 2014
6
Why plants for Molecular farming?
Plants had the potential to produce complex mammalian proteins of medical importance.
Low cost of production.Stability – storage by freezing or drying leaves.Safety - free from animal and human virus.Arabidopsis thaliana is used as model plant.Easily reproducible in consumable form viz. cereals, leafy crops,
fruits and vegetables.
Sahu et al., 2014
SPECIES BENEFITS LIMITATION
MODEL PLANT : Arabidopsis thaliana
Mutant available Small genome Accessible genetics
Low biomass
LEAFY CROPS: Tobacco
High biomass Rapid scale up Non-food/ feed crop
Low protein stability Presence of toxic alkaloids
Alfalfa
High biomass yield Harvested up to six times/yr. Fixes the atmospheric N2 .
Low protein stability
Lettuce Can take as edible part Low protein stability
CEREAL SEED : Maize, Rice, Wheat
High protein stability during storage. High yield. Easy transformation and scalability.
Difficulty in downstream processes
Plants most often used
Sahu et al., 2014
LEGUME SEED: Pea and Soybean
High protein stability during storage. High yield. Easy transformation and scalability. Fixes the atmospheric N2 .
Difficulty in downstream processes
FRUITS AND VEGETABLES: Potato
Edible Bulk antibody production High biomass yield
Cooking or boiling degrade the protein
Tomato
High biomass yield Edible
Greenhouse require Low protein stability
Banana
Edible Less costly
Low protein stability
FIBER AND OIL-SEED CROPS:
Flax, Cotton, Safflower
Oleosin fusion protein Fiber and oil can interfere with downstream processing
Sahu et al., 2014
9
Comparison of expression systems
Expression system
Yeast Bacteria Plant cell culture
Transgenic plants
Transgenic animal
Animal cell culture
Cost of maintaining
Inexpensive Inexpensive Inexpensive Inexpensive Expensive Expensive
Type of storage (ͦ C)
-2.0 -2.0 -2.0 RT N2 N/A
Gene(protein) size
Unknown Unknown Limited Unlimited Limited limited
Production cost
Medium Medium Low Low High High
Protein yield High Medium Very high High Medium High
Ramalingam et al., 2014 Coimbatore
10
Different plant based expression systems
1. Stable nuclear transformationMost commonUsed in a species with a long generation cycle Foreign genes are transfer via Agrobacterium tumefaciens or
particle bombardmentGenes are taken up and incorporated in a stable mannerLarge acres can be utilized with the lowest cost- grains Long-term non-refrigerated storage of the seed up to 2 yrsManual labor requiredLower yield and out-crossing
Obembe et al.,2011
11
2. Plastid transformationFirst described by Svab et al. (1990) No transgenic pollen is generated Very high expression levels can be achievedProtein – up to 70% on dry weight but relatively stableNo out-crossing
Protein unstableExtraction and purification at specific timeEdible vaccine is not feasible since tobacco is highly regulated
Scotti et al., 2010
12
3. Transient transformationRecombinant plant viruses to infect host plants, like TMV,
CaMV, PVXAgroinfiltration through recombinant A. tumefaciensSmall amounts target protein is obtained in weeksInfection process is rapidProtein accumulate in the interstitial spaces
Target protein is temporary express in the plantNo long term storage due to tissue damageNo stable transgenic plants are generatedLow scalability and expression levels
Komarova et al., 2010
Transient transformation
13 Komarova et al., 2010
4. Stable transformation for hydroponicsTransgenic plants are grown on hydroponic medium
Desired products are released as part of root fluid into a hydroponic medium
Plants are contained in greenhouse
Easier purification but expensive to operate
Not suitable for large scale production
14
Downstream processing and recovery
15
16
Applications
Parental therapeutics and pharmaceutical
intermediates
Industrial proteins and enzymes
Monoclonal antibodies
Biopolymers Antigens for edible
vaccines
17
Monoclonal antibody (mAb)Antibody that is produced by genetically engineered Plant i.e. insertion
of antibodies into a transgenic plant; referred to as plantibodyBiolex (North Carolina) is the trademark for Monoclonal antibody No risk of spreading diseases to humansHiatt. et al (1989): First time demonstrate the production of antibodies
in tobacco as therapeutic protein and plant protection against diseasesDaniel (2002) was reported that due to the lack of glycosylation,
chloroplast transformation is ideal for single chain fragment(scFv)Agrofiltration is ideal for transient expression of heavy and light chain
genes All current therapeutic antibodies are of the IgG classPurification is done through processes such as filtration,
immunofluorescence, and chromatography
Plant Cell Transformation
Agrobacterium Mediated Transfer of Antibody Genes
Direct Gene Transfer by Gene Gun
Plant Development and propagation in fields
Insertion of Transformed Cell into Plant tissue
Harvested and downstream processing
Method of antibody production
18
Antibodies from transgenic plantsPlant Antibody type Purpose ReferencesTobacco IgG Catalytic antibodies Hiatt et al., 1989
Tobacco IgG-colon cancer Systemic injection Verch et al., 1998
Alfalfa IgG-human Diarrhea Diagnostic Khoudi et al., 1999
Tobacco IgG-rabies virus Anti rabies virus Ko et al., 2003
Tobacco IgG-hepatitis B virus hepatitis B surface antigen Yano et al., 2004
Tobacco IgG-Anthrax Monoclonal antibody Hull et al.,2005
Tobacco IgG-rabies virus Human anti rabies virus Girard et al., 2006
Tobacco BoNT antidotes Botulinum neurotoxins (BoNTs)
Almquist et al., 2006
Tobacco mAb 2F5 Activity againstHIV-1
Sack et al., 2007
Tobacco LO-BM2, IgG Therapeutic De Muynck et al., 2009
Tobacco mAb H10 Tumour-associatedantigen tenascin-C
Villani et al., 2009
Obembe et al., 201119
20
Production costs for antibodies
Production cost Cost in $ per gramHybridomas 1000Transgenic animals 100Transgenic plants 10
Daniell et al., 2001
E. coli & yeast Tr. animals andanimal cells
Transgenic plants
21
Edible vaccines
A vaccine developed by engineering a gene for an antigenic protein
into a plant.
The concept of edible vaccine got incentive after Arntzen et al.
(1992) expressed hepatitis B antigen in tobacco.
Expressed in the edible portion like tubers, fruits etc.
Due to ingestion, it releases the protein and get recognized by the
immune system.
Stimulate both humoral and mucosal immunity.
It is feasible to administer unlike injection.
Heat stable - no need of refrigeration.Kumar et al., 2013
22
Method for the production edible vaccine
Figure : Edible vaccine production methods
23
Plant-derived oral vaccines
Chan et al., 2015
Pathogen Antigen Plant References
Major capsid protein VP6 Potato Langridge et al. (2003)
Hepatitis B virus Surface antigen Potato Youm et al. (2010)
Human immunodeficiency virus (HIV-1)
p24-Nef Tobacco Gonzalez-Rabade et al. (2011)
HIV-1 C4(V3)6 multi-epitopic protein
Lettuce Govea-Alonso et al. (2013)
Human papillomavirus (HPV) HPV16-L1 Tobacco Liu et al. (2013)
HPV HPVL1-E6/E7 Tomato Monroy-Garcıa et al. (2014)
Influenza virus H3N2 nucleoprotein Maize seeds Nahampun et al. (2015)
Vibrio cholerae CTB Rice seeds Tokuhara et al. (2010)
Rabies virus G protein Tomato hairy roots
Singh et al. (2015)
24
Outline
Candidates for edible vaccine
25
Industrial enzymes
Seon et al., 2002
Enzyme Plants Applicationsα- Amylase Tobacco Food processing
Avidin Corn / maize In diagnostic kits
Cellulase Brassica Production of alcohol from cellulose
β- glucanase Brassica In brewing industry
β- glucuronidase Brassica In diagnostic kits
Lignin peroxidase Wheat In paper manufacture
Phytase Rice Improved phosphate utilization
Trypsin Maize Pharmaceutical
Xylanase Brassica Biomass processing, paper and textile industries
26
Industrial products close to marketProduct Company Uses References
Trypsin ProdiGene pharmaceutical Woodard et al., 2003
GUS ProdiGene Reagent for diagnostics
Kusnadi et al.,1998
Avidin ProdiGene Immunological reagent
Hood et al.,1997
Aprotinin Large scale Biology Wound closure Zhong et al.,1999
Collagen ProdiGene,Medicago
Gel cap Ruggiero et al., 2000
Lipase Meristem therapeutics
Exocrine pancreatic insufficiency
Gruber et al.,2001
Lactoferrin Ventria Natural defense Samyn-petit et al., 2001
TGEV edible vaccine
ProdiGene Swine Lamphear et al., 2002
27
Case Studies
Expression of Cholera Toxin B Subunit in Transgenic Rice Endosperm
•Cholera is an extremely epidemic diarrheal disease, which continues to devastate many developing countries.
•Synthetic cholera toxin B subunit (CTB) gene, modified according to the optimized codon usage of plant genes,
•Introduced into a plant expression vector and expressed under the control of the Bx17 HMW (high molecular weight) wheat endosperm-specific promoter containing an intron of the rice act1.
•The recombinant vector was transformed into rice plants using a biolisticmediated transformation method.
Hungary Oszvald et al., 200828
• The synthetic CTB gene (sCTB) fragment was removed from pMYO114 via digestion with KpnI and NcoI. It was inserted into the plant expression vector, pMYN317, under the control of the Bx17 endosperm specific promoter with the first intron of rice act1 and the terminator of nopaline synthase (NOS) gene.
Construction of Plant Expression Vector
• The plant expression vector was transformed into rice cells (Oryza sativa L.) via a biolistic-mediated transformation method
Plant Transformation
• The presence of synthetic CTB was verified via PCR analysis. The primer pairs were sCT1-F and sCT5-dk-R.
Detection of sCTB Gene in Transgenic Plants
• Total RNA was extracted from the mature rice seeds of transgenic plants harboring the sCTB gene and wild-type plants.
• The blots were hybridized with a 32P-labeled random-primed.
Northern Blot Analysis
• The membranes were incubated for 2 h with 1:7,000 dilutions of anti-rabbit IgG conjugated with alkaline phosphatase (Promega S3731) in TBST buffer.
Immunoblot Detection of CTB Protein in Transformed Rice Seeds
Quantification of CTB Protein Level in Transgenic Rice SeedsGM1-Binding Assay29
Synthetic CTB gene (sCTB) fused with SEKDEL was under the control of Bx17 HMW endosperm-specific promoter (HMW-Bx17-p) with the first intron of rice act1 gene (Act1-i).
Hygromycin phosphotransferase gene (hpt) as a selection marker gene is under the control of Agrobacterium tumefaciens nopaline synthase gene promoter (NOS-p) and terminator (NOS-t).
BSP is bacterial signal peptide from enterotoxigenic E-coli heat-labile enterotoxin B subunit (LTB)
Plant expression vector
30
Fig: PCR and Northern blot analysis of transgenic rice plants
(A)PCR analysis of transgenic and wild-type plants was conducted to amplify the sCTB gene. Lane PC is plant expression vector used as a positive control for PCR; lane WT is wild type plant used as a negative control; lanes 1–7 are PCR products amplified from the DNA templates of independent transgenic lines.
(B) Northern blot analysis of transgenic and wild-type plants using a 32P-labeled sCTB probe. Lane WT is wild-type plant as a negative control; lanes 1–7 are transgenic lines
PCR and Northern blot analysis
31
Western blot analysis of CTB protein expressed in the endosperm of transgenic rice plants. Total soluble protein extracts (15 µg) from the endosperm of wild type (WT) and transgenic plants along with 80 ng of purified bacterial CTB protein were separated on 12% SDS-PAGE. Denatured proteins in B were boiled for 10 min prior to loading on the gel. Arrows indicate monomer or pentamer of plant-produced CTB
Western blot analysis
32
(A)The CTB expression level (% of TSP) in the mature endosperm of transgenic rice plants #2, 5, and 6 showing high expression levels of CTB transcripts in Northern blot analysis was determined by ELISA in triplicate.
(B) GM1 binding assay of plant-produced CTB proteins. The GM1 -ELISA was conducted with coated GM1 ganglioside as receptor molecules or BSA (bovine serum albumin) as a negative control.
ELISA quantification
33
34
Production of highly concentrated, heat stable hepatitis B surface antigen in maize
Celine A. Hayden1, Erin M. Egelkrout1, Alessa M. Moscoso1, Cristina Enrique1, Todd K. Keener1, Rafael Jimenez-Flores2, Jeffrey C. Wong3, and John A. Howard1
Plant Biotechnology Journal. 2012 October ; 10(8): 979–984.
Hayden et al., 2012California
• Over 350 million people are chronically infected with the hepatitis B virus worldwide.
• HBsAg is a membrane-bound protein, a class of proteins that are typically difficult to express in heterologous systems, so they have used a new construct.
• These DNA constructs demonstrate improved accumulation of HBsAg over previously reported material and deliver maize grain suitable for oral vaccination that is cost effective, heat stable, and highly concentrated.
35
Construct design
Construct design for the production of HBsAg in Zea mays. glb1, 1.4kb globulin1 promoter; 3kbglb1, extended globulin1 promoter; 3xglb1, tandemly repeated extended globulin1 promoter; BAASS, barley alpha amylase signal sequence; Vac, Vacuolar targeting sequence; HB, hepatitis B surface antigen; PinII, potato proteinase inhibitor II termination sequence. All constructs also contained an herbicide resistance gene following the PinII termination sequence. Hayden et al., 2012
36
Single Seed Desent method
Enzyme Linked Immuno Sorbent Assay (ELISA)
Comparison
Construct Total Soluble Protein (%)
Construct target site
HBE (Standard)
0.12Cell wall targetting signal
HBF 0.31
Cell wall targetting signalHBG 0.41
HBJ 0.51
HBK 0.15 Vacuolar targetting signal
T- DNA with construct
A. tumifaciens with T- DNA Hi II Maize
GermplasmNon – transgenic Hi II Parent
Backcross
Hayden et al., 2012
37
HBsAg accumulation in single seeds from the first generation
Hayden et al., 2012
0.12%
0.31%
0.41%
0.51%
0. 15% 0.05%
0.17%
0.27% 0.26%
HBsAg concentration in second generation (T2) ears with highest antigen accumulation, as determined by ELISA
Antigen detection by ELISA
38
Effect of maize processing and temperature treatments
Total soluble protein and HBsAg protein content in HBsAg maize seed stored at −20°C, 55°C, and 80°C for one week.
Total soluble protein (mg protein/g maize material ± S.D)
HBsAg (μg antigen/g maize material ± S.D)
−20°C 55°C 80°C −20°C 55°C 80°C Full fat 21.7 ±
1.7 21.1 ± 0.3
2.9 ± 0.6
55.8±5.5
27.8±12.2
<0.1
Hexane-treated
20.2 ± 0.4
19.6 ± 0.2
12.4 ± 4.4
51.2±3.7
41.1±5.0
0.3±0.6
SFE-treated 20.4 ± 1.5
19.5 ± 0.7
14.9 ± 5.1
45.9±4.4
48.5±4.4
1.7±1.7
Hayden et al., 2012
Effect of oil extraction and temperature on maize-produced HBsAg, as determined by immunoblot.
39
A- Full Fat:High level of lipids
B- Hexane treated :Medium level of lipids
C- SFE treated :Low level of lipids
Confocal microscopy :Presence of protein(fast Green) and lipids(Nile Red)
Hayden et al., 2012
Avian influenza is one of the most dangerous diseases to domestic poultry. Mass vaccination of domestic and wild birds is the best method for preventing its spread.
Antigenic variation of this virus hinders vaccine development.Extracellular domain of the virus-encoded M2 protein (peptide M2e)
is nearly invariant in all influenza A strains, enabling the development of a broad-range vaccine against them.
Aleksey et al., 2015Jerusalem, Israel
High-Yield Expression of M2e Peptide of Avian Influenza Virus H5N1 in Transgenic Duckweed Plants
Aleksey Firsov • Irina Tarasenko • Tatiana Mitiouchkina •Natalya Ismailova • Lyubov Shaloiko •Alexander Vainstein • Sergey Dolgov
40
•plasmid (pBIM130) was transferred into Agrobacteriumtumefaciens CBE21 ->used for transformation of duckweed pBI121 in the translational fusion upstream of the b-glucuronidase geneConstruction
of the Transformatio
n Vector
•The calluses were used for agrobacterial transformation
Agrobacterial Transformati
on of Duckweed
•The activity of b-glucuronidase in duckweed was analyzedusing the histochemical methodGUS-Expression
Assays
•PCR analysis of putatively transgenic plants was performedusing primers M130F and uidAlowR
PCR Analysis
•Duckweed genomic DNA (50ug) + 100U EcoRI + 37C, Overnight
•pBI121 and digested with EcoRI and HindIII was used as a positive control
Southern Blot Analysis
•Total proteins (25 lg) from each transgenic line were separated by 12 % SDS-PAGE and transferred onto an NC membrane + ELISA Quantification of M130–b-Glucuronidase accumulation.
Western Blot Analysis
41
Fig. Schematic depiction of the expression cassette of plasmid pBIM130. A. Nucleotide sequence of the DNA fragment encoding the peptide M130. B. Expression cassette obtained after cloning the M130-encoding sequence
into plasmid pBI121
42
A: Frond regeneration from kanamycin-resistant callus after 10 weeks of growth on NPM regeneration medium.
B–F: X-Gluc staining of nontransformed control and kanamycin-resistant duckweed plants.
B & C: Transgenic lines 16 and 54, respectively, with high GUS expression.
D & E: Transgenic lines 19 and 34, respectively, with moderate GUS expression.
F: Nontransformed duckweed plants. G: Transgenic duckweed plants (line 54) growing on LHFM medium
with kanamycin
PCR analysis
A: K- nontransformed plant, K+ DNA of plasmidpBIM130. The expected length of the amplified fragment was 1024 bp. Numbers denote independent transgenic lines.
B: Southern blot analysis of transgenic duckweed lines. 1 transgenic duckweed line 54, 2 nontransformed plant, 3 duckweed plants transformed with pBI121, 4 transgenic duckweed line 72, M molecular size marker
Western blot analysis
Western blot analysis using A: anti-β-Glucuronidase antibody and B: anti-M2e antibody. K- nontransformed duckweed plants, gus β -Glucuronidase from E. coli (25 µg), M molecular size marker. Numbers denote transgenic lines; arrow indicates M130–β-Glucuronidase fusion protein
Fig. Quantification of M130–β-glucuronidase fusion protein in transgenic duckweed plants. K- nontransformed plants. Numbers denote transgenic lines. Error bars indicate ± SD
45
There are two separate categories of risk. 1. Gene and protein pollution- Transgene and their encoded
proteins could spread in the environment and could be affect non-target organisms. Ultimately, humans could be affected by the consumption of food containing such genes or recombinant proteins.
2. Product safety- Such pharmaceutical products and concerns the risk that such products could be harmful in the human or animal patients to which they are administered.
Biosafety issues in molecular farming
46
Vertical gene transferGene flow from transgenic to non-transgenic populations of the
same crop could occur by this method if the two populations were close enough for wind- or insect mediated pollen transfer.
In this case, transgene pollution would occur via seed dispersal, either during growth, harvesting or during transport.
Horizontal gene transfer Risk that horizontal gene transfer from transgenic plants to
bacteria in the soil or in the digestive systems of herbivores could yield new bacterial strains.
These traits could have unpredictable effects on relationships between different organisms.
47
ConclusionPlants are effective and efficient bioreactors for the production of
pharmaceutically valuable recombinant proteins. Variety of plant species that are being explored to serve as green bioreactors, each with its own advantages and disadvantages.
Transgenic plant shows low production cost, high productivity, no risk of contamination and easy storage compared to transgenic animal. Thus it serves as an alternative to conventional fermentation systems that use bacteria, yeast or mammalian cells.
PMPs have already achieved preclinical validation in a range of disease models like hepatitis B, rabies etc.
48
Plant-derived pharmaceuticals will need to meet the same safety and efficacy standards as those products obtained from non-plant sources.
We must ensure that the potential benefits are not outweighed by risks to human health.
Plant based recombinant therapeutics can neither commercially succeed nor be accepted without addressing proper biosafety and immunogenicity issues.
Efforts are required to make this technology non-allergic and free from side effects.
Future thrust
49
EDIBLE VACCINE
PARENTERAL VACCINE
Thank You